Tempo differito
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
44,08 CHF | +2,55% |
|
-.--% | -6,91% |
21:14 | La terapia per il cancro colorettale di Bristol-Myers Squibb riceve l'approvazione della FDA | MT |
19:27 | La FDA statunitense approva la terapia per il cancro colorettale di Bristol Myers | RE |
Attività
Gli Stati Uniti rappresentano il 70,1% delle vendite nette.
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 46 159 | 100,0 % | 45 006 | 100,0 % | -2,50% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
70,1
%
| 31 828 | 69,0 % | 31 555 | 70,1 % | -0,86% |
International
28,3
%
| 13 497 | 29,2 % | 12 752 | 28,3 % | -5,52% |
Other
1,6
%
| 834 | 1,8 % | 699 | 1,6 % | -16,19% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Chief Executive Officer | 53 | 01/02/15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/11/19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 01/01/03 | |
Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/01/19 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/11/19 |
Laura Hortas
IRO | Public Communications Contact | - | - |
Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20/11/19 |
Peter Arduini
BRD | Director/Board Member | 59 | 01/04/16 |
Derica Rice
BRD | Director/Board Member | 59 | 01/09/20 |
Paula Price
BRD | Director/Board Member | 62 | 01/09/20 |
Theodore Samuels
BRD | Director/Board Member | 69 | 21/02/17 |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/11/19 |
Chief Executive Officer | 53 | 01/02/15 | |
Julia Haller
BRD | Director/Board Member | 69 | 20/11/19 |
Karen Vousden
BRD | Director/Board Member | 66 | 01/01/18 |
Director/Board Member | 56 | 01/06/21 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 2 923 100 096 | 2 024 918 592 ( 69,27 %) | 896 000 000 ( 30,65 %) | 69,27 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
5 075 304 | 5.31% | 136 322 665 $ | |
759 145 | 6.36% | 19 358 198 $ | |
COMPUGEN LTD. 5.31% | 4 757 058 | 5.31% | 10 322 816 $ |
CELULARITY INC. 5.49% | 1 195 327 | 5.49% | 3 717 467 $ |
Coordinate società
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.com![Indirizzo Bristol-Myers Squibb Company(BMY)](https://cdn.zonebourse.com/static/address/149358858.png)
Società del gruppo
Nome | Categoria e settore |
---|---|
Bristol-Myers Squibb India Pvt Ltd.
![]() Bristol-Myers Squibb India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb India Pvt Ltd. is an Indian company that discovers, develops, and delivers medicines for immuno-oncology. The company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb de México S de RL de CV
![]() Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The company is located in Mexico. |
Pharmaceuticals: Major
|
Celgene Kappa Holdings LLC
| |
Bristol-Myers Squibb International Co. ULC
| |
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH
| |
Seamair Insurance DAC
![]() Seamair Insurance DAC Insurance Brokers/ServicesFinance Part of Bristol Myers Squibb Co., Seamair Insurance DAC is an Irish company that provides insurance services. The company is based in Dublin, Ireland. |
Insurance Brokers/Services
|
Bristol-Myers Squibb AE
| |
Swords Laboratories Unlimited Co.
![]() Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland. |
Pharmaceuticals: Major
|
BMS Strategic Portfolio Investments Holdings, Inc.
|
Settore
Vendite per regione
![Consenso](/images/consensus_flch.gif)
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+51,63% | 798 Mrd | |
+41,51% | 633 Mrd | |
-5,10% | 356 Mrd | |
+19,90% | 328 Mrd | |
+9,95% | 304 Mrd | |
+17,66% | 244 Mrd | |
+3,39% | 227 Mrd | |
+10,75% | 216 Mrd | |
+6,99% | 166 Mrd |
- Borsa valori
- Azioni
- Azione BMY
- Azione BMY
- Società Bristol-Myers Squibb Company